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AbstrACt
Introduction Breakthrough pain is common in children 
and adults with cancer and other conditions, including those 
approaching end- of- life, although it is often poorly managed, 
possibly partly due to a lack of validated assessment tools. 
This review aims to (1) identify all available instruments 
measuring breakthrough pain in infants, children, 
adolescents or adults and (2) critically appraise, compare and 
summarise the quality of the psychometric properties of the 
identified instruments using COnsensus- based Standards for 
the selection of health Measurement INstruments (COSMIN) 
criteria.
Methods and analysis Two searches will be carried out 
between October 2019 and January 2020, one for each 
aim of the review. The Cochrane Library, International 
Prospective Register of Systematic Reviews, Embase, 
Cumulative Index of Nursing and Allied Health Literature, 
Medical Literature Analysis and Retrieval System Online 
(MEDLINE), PsycINFO, Web of Science Core Collection, 
Google Scholar, the ProQuest Dissertations & Theses 
Database, Evidence Search and OpenGrey databases will 
be searched from database inception until the date the 
search is conducted. Reference lists of eligible articles will 
be screened and authors in the field contacted. For search 
1, articles will be screened by two reviewers by abstract, 
and full- text where necessary, to identify if a breakthrough 
pain assessment was used. Search 2 will then be conducted 
to identify studies evaluating measurement properties of 
these assessments. Two reviewers will screen articles from 
search 2 by title and abstract. All potentially relevant studies 
will be screened by full text by both reviewers. For search 2, 
data will be extracted in parallel with the quality assessment 
process, as recommended by COSMIN. Two reviewers will 
assess methodological quality using the COSMIN Risk of 
Bias checklist and the COSMIN updated criteria for good 
measurement properties. Findings will be summarised and, if 
possible, data will be pooled using meta- analysis. The quality 
of the evidence will be graded and summarised using the 
Grading of Recommendations, Assessment, Development 
and Evaluations (GRADE) guidelines.
Ethics and dissemination Results of this review will 
be submitted for publication in a peer review journal and 
presented at conferences.
PrOsPErO registration number CRD42019155583.
IntrOduCtIOn
Even though the diagnosis, assessment, and 
treatment, of breakthrough pain (BTP; 
figure 1) has dramatically improved in recent 
years, BTP continues to present a significant 
clinical challenge for patients, their care-
givers, healthcare professionals and health-
care systems. While BTP is often experienced 
by people with cancer1 2 it is also seen in 
patients with other conditions,2 3 including 
those with terminal diseases approaching 
end- of- life.4 The reported prevalence of BTP 
varies significantly across studies5 primarily 
due to variability in the definitions of BTP 
and methods used to assess it, study designs, 
strengths and limitations of this study
 ► This review will follow both the Preferred Reporting 
Items for Systematic Review and Meta- Analysis and 
the COnsensus- based Standards for the selection of 
health Measurement INstruments methodologies for 
conducting systematic reviews.
 ► Eleven databases will be searched, including those 
that store doctoral dissertations and other types of 
grey literature.
 ► The use of English language restriction may in-
troduce a language bias and lead to erroneous 
conclusions.
 ► The limited literature on breakthrough pain assess-
ment tools may prevent quantitative pooling of data 
(ie, meta- analysis).
 ► Patient and public involvement is ensured at key 
stages of the review, that is, development of the 
research question, helping to determine the appro-
priate inclusion and exclusion criteria and identifying 
search terms and relevant outcomes, and peer re-
viewing academic papers.
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Figure 1 Graphical representation of breakthrough pain.
settings and disease groups. In a recent systematic review 
of 19 studies and more than 6000 adult patients with 
cancer pain, the prevalence of BTP ranged from 33% to 
95%, with an overall pooled prevalence of 59.2%.6 That 
is comparable to the reported prevalence of BTP pain in 
adults with chronic non- cancer pain.5 7 Similarly, BTP is 
common in children with cancer or life- limiting condi-
tions (LLCs),8 9 including those with communication 
and/or learning difficulties as well as pre- verbal infants, 
for which assessment of BTP is a particular challenge. 
The single small study investigating BTP in a popula-
tion of children with LLCs10 showed that 57% out of 27 
hospitalised children with cancer who had controlled 
background pain reported having experienced BTP in 
the previous 24 hours. A retrospective review of clinical 
records showed that younger children (aged 7–12 years) 
had a significantly higher risk of BTP compared with 
teenagers and children and that children can experience 
BTP even when following a pain management strategy to 
control background pain.9
Despite ongoing international efforts for over 20 
years, consensus on the definition of BTP has not yet 
been achieved.11 In the cancer literature, Portenoy and 
Hagen12 proposed the following working definition for 
breakthrough cancer pain (BTCP): ‘a transitory exacer-
bation of pain experienced by patients undergoing long- 
term opioid treatment for cancer- related pain whose 
baseline pain is adequately controlled’. However, more 
recent definitions do not include regular opioid medi-
cation13 or background pain as prerequisites for BTCP.14 
The expert working group of the European Association 
for Palliative Care recommended the use of a simpler term 
such as ‘episodic’ or ‘transient’ pain, as the English term 
‘breakthrough’ has no literal translation in many other 
languages. The WHO defines BTP in broader terms as ‘a 
temporary increase in the severity of pain over and above 
the pre- existing baseline pain level’. According to the 
WHO,15 BTP is usually sudden, severe and occurs in brief 
episodes that can happen multiple times a day.15 In the 
11th edition of the International Classification of Diseases 
(ICD-11), a task force of the International Association for 
the Study of Pain describes cancer pain as continuous 
(background pain) or intermittent (episodic) pain.16 
The latter is defined as either related to movement or 
activity (incident pain) or unrelated (spontaneous pain). 
Nonetheless, BTCP specifically is not listed in the ICD-11. 
BTP can have various pathophysiologies (nociceptive, 
neuropathic, mixed) and multiple causes or comorbidi-
ties. Adults with BTP report markedly reduced quality of 
life, functioning and productivity compared with patients 
with chronic pain and no BTP, and those without clini-
cally significant pain.5 Evidence suggests that this type of 
pain may also detrimentally affect the mental and phys-
ical well- being of patients and caregivers.17 18 There is a 
paucity of research on short/longer- term effects of BTP 
in infants, children and young people.8
A recent systematic review concluded that current 
guidelines agree on many aspects of the management of 
BTCP. However, the evidence to support current guide-
lines remains low grade, and more research is needed in 
this area of care along with an international consensus 
on the definition and diagnostic criteria of BTCP.19 It 
is important that patients are assessed to ensure that 
background pain and BTP are differentiated20 21 and 
that BTP is not misdiagnosed as ‘end- of- dose failure’ of 
around- the- clock treatment, or as pain occurring when 
opioid medication is started or titrated.21 22 While there 
are a number of validated pain assessment instruments, 
there is a lack of measures for BTP specifically.23 24 These 
are needed since the unique features of BTP are often 
not picked up by existing pain assessment tools (eg, its 
temporal features and triggers).25
Existing BTP assessment tools for use in adults include 
the Breakthrough Pain Questionnaire (BPQ)12; the 
Alberta Breakthrough Pain Assessment Tool for Cancer 
Patients (ABPAT),26 the Breakthrough Pain Assessment 
Tool (BAT)27 and the Italian Questionnaire for BTP (IQ- 
BTP).7 The ABPAT is completed by a clinician with the 
patient, while the BPQ, BAT and IQ- BTP are self- reported 
questionnaires. The ABPATwas developed primarily for 
use in research and is considerably longer (26 questions) 
than the BAT (14 questions), which was designed for use 
in clinical settings. However, the BAT only assesses the 
characteristics of previously diagnosed BTP, rather than 
diagnosing BTP. Oostendorp et al9 aimed at generating 
reliable information on the nature and management 
of paediatric BTP from narrative clinical records. The 
authors piloted a BTP data extraction instrument based 
on a glossary of BTP terms developed by 13 clinicians. 
However, this showed poor agreement between raters, 
highlighting the need for clear BTP criteria, a structured 
way to document BTP, and validated assessment tools 
for use with children. BTP assessment tools designed for 
adults may not be suitable for children due primarily to 
developmental and disease differences.
Although recent reviews have investigated the preva-
lence6 and/or management19 24 28 of BTP, and one 2010 
review23 looked at BTP classification and assessment, to 
our knowledge, there are no recent published system-
atic reviews assessing the measurement properties of 
BTP assessment tools for people of all ages. It is clear 
that for pain to be successfully managed and treated, it 
is important that it is assessed, monitored and re- assessed 
effectively. As such, the main objectives of this systematic 
review are to
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1. Identify all available instruments assessing self/
caregiver- reported BTP in infants, children or adults.
2. Critically appraise, compare and summarise the quality 
of the measurement properties of the identified instru-
ments using COnsensus- based Standards for the selec-
tion of health Measurement INstruments (COSMIN) 
criteria.29
MEthOds
This protocol follows the Preferred Reporting Items for 
Systematic Review and Meta- Analysis Protocols (PRISMA) 
guidelines.30 31 The systematic review follows the PRISMA 
and the COSMIN guidelines.32 33 Details of the protocol 
are registered on the International Prospective Register of 
Systematic Reviews (PROSPERO) registry. Any protocol 
amendments will be reported in the systematic review 
publication. The planned start date for this review is 22 
September 2019 and the planned end date is 22 March 
2020.
Eligibility criteria
Our study selection criteria were guided by the COSMIN 
group guidelines.29
Inclusion criteria
1. All studies and PhD theses (since these are formally 
peer- reviewed) published from the inception of each 
database, which involve any type of BTP assessment 
instrument or measure (eg, questionnaire, inventory, 
self- report, caregiver- report) for objective 1; or that 
aim to develop and/or evaluate one or more measure-
ment properties of a BTP assessment instrument for 
objective 2.
2. Measures might include duration, intensity and/or 
frequency of BTP or its impact on the individuals, for 
example, functional disability. All definitions of BTP 
will be included since there is a lack of consensus on 
an established definition.
3. Studies carried out worldwide that involve patient or 
caregiver assessment of BTP in infants, children or 
adults of all ages. Caregivers will include carers, family, 
parents and healthcare professionals.
Exclusion criteria
1. Articles written in any language other than English.
2. Masters theses, conference abstracts, reviews.
3. Studies that involve pain assessments but do not assess 
BTP specifically.
searches
Two searches will be run, one for each objective of the 
review. Search 1 will aim to identify all available instru-
ments measuring self/caregiver- reported BTP in infants, 
children or adults. Search 2 will aim to identify all studies 
that evaluate measurement properties included in the 
main domains (reliability, validity, responsiveness and 
interpretability) of the COSMIN taxonomy34 (see table 1).
Electronic sources
The Cochrane Library and PROSPERO will be searched 
initially to check for any existing systematic reviews on 
this topic. Embase, Cumulative Index of Nursing and 
Allied Health Literature (CINAHL), Medical Literature 
Analysis and Retrieval System Online (MEDLINE) (both 
via Ebsco), PsycINFO, the Web of Science Core Collec-
tion and the advanced Google Scholar search facility 
(pdfs only, first 50 records) will then be searched. To 
identify any additional unpublished work, the ProQuest 
Dissertations and Theses Database, Evidence Search and 
OpenGrey will also be searched. The search strategy will 
include hand searching of reference lists of relevant 
studies for additional records. No limits will be placed 
on publication date when conducting the searches, with 
each database searched from database inception until 
the date on which the search is conducted. Finally, active 
researchers in the field who have contributed to this liter-
ature will be contacted. All searches will be run between 
October 2019 and January 2020.
Search terms
Search 1 will comprise of two blocks: (1) BTP and (2) 
assessments. Search 1—block 1 will include the following 
terms: ‘breakthrough pain’ OR ‘break through pain’ OR 
‘break- through pain’ OR ‘BTP’ OR ‘incident pain’ OR 
‘incidental pain’ OR ‘episodic pain’ OR ‘transient pain’ 
OR ‘transitory pain’ OR ‘spontaneous pain’ or ‘pain 
flare’.
Search 1—block 2 will include terms describing assess-
ments such as: apprais* OR report* OR rated OR rating* 
OR assess* OR index OR indices OR instrument* OR 
measure* OR questionnaire* OR profile* OR scale* 
OR score* OR status OR survey* OR construct* OR 
development*.
Combinations of keywords, text words, Medical Subject 
Headings (MeSH) and other terms relevant to the review 
question will be chosen for each database to optimise the 
search sensitivity and specificity. The search strategy will 
be piloted and adapted for each database.
Search 2 will include two blocks: (1) terms to identify 
the BTP assessments found in search 1 and (2) measure-
ment properties of these assessments. Once the BTP 
assessments have been identified from search 1, the terms 
used in search 2—block 1 will be developed.
Search 2—block 2 will include the COSMIN search 
filters for identifying studies on measurement proper-
ties in Medline, Embase, PsycINFO and CINAHL. Since 
the remainder of the databases do not have a COSMIN 
search filter, only block 1 will be used for the remaining 
databases.
data management
All records and data will be saved to Endnote X8.35 This 
software will be used to identify potential duplicates. The 
researchers will check these and remove all confirmed 
duplicated references.
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Table 1 Measurement properties included in the main domains of the COSMIN taxonomy
Domain
Psychometric 
property Definition
Reliability The extent that the measurement is free from measurement error such that scores for 
patients who have not changed are the same under repeated measurements
Internal consistency The extent that items are inter- related
Reliability The proportion of the total variance in the measurements that is due to ‘true’ 
differences between patients (as opposed to error)
Measurement error Error in a participant’s score that is not attributed to the construct being measured
Validity The extent that an assessment measures what it aims to measure
Content validity The extent that an assessment’s content reflects the construct being measured
Face validity The extent that an assessment looks like it reflects the construct being measured
Construct validity The extent that an assessment’s scores are consistent with hypotheses based on the 
assumption that the tool measures what it purports to measure
Structural validity The extent that an assessment’s scores reflect the dimensionality of the construct 
being measured
Hypothesis testing Construct validity for the items of an assessment
Cross- cultural validity The extent that items on a translated or culturally modified assessment reflect the 
original items
Criterion validity The extent that an assessment’s scores represent the ‘gold standard’
Responsiveness An assessment and/or it’s items’ ability to detect change over time in the construct 
being measured
Interpretability* The extent that clinical or everyday understanding can be applied to an assessment’s 
scores
*Interpretability is not considered a measurement property, but an important characteristic of a measurement instrument.
COSMIN, COnsensus- based Standards for the selection of health Measurement INstruments.
selection process
For search 1, two reviewers (KG and SH) will identify if a 
BTP assessment was used in each article. This will involve 
screening each article by abstract and by full text where 
necessary.
For search 2, articles will be screened by title and 
abstract by two reviewers (KG and SH) independently. 
At this stage, articles will be judged as either (a) ‘not 
relevant’ or (b) ‘potentially relevant’. Inter- coder agree-
ment will be evaluated using Cohen’s kappa coefficient. 
A minimum kappa value of 0.75 will be taken to repre-
sent high agreement.36 We will retrieve the full text of all 
remaining potentially relevant articles. If the relevance of 
a study cannot be ascertained from the abstract, then we 
will obtain the full text. These will be read by two reviewers 
(KG and SH) to make the final decision regarding inclu-
sion. If needed, further details will be sought from authors 
and any uncertainties will be resolved via discussion with a 
third reviewer (CL).
data collection process and quality assessments
For search 1, if a BTP assessment was used in an article, 
both the article and the name of the assessment will be 
recorded. The article will not be assessed further unless 
it meets the criteria for the second objective (studies that 
evaluate one or more properties of a BTP instrument). For 
search 2, data will be extracted in parallel with the quality 
assessment process, as recommended by COSMIN.29
For all included studies found from search 2, the 
following information will be extracted into a piloted data 
collection form: study aims, used definition of BTP, study 
population characteristics (including setting, country, 
language, disease characteristics, sample size, age range 
and gender), characteristics of the BTP assessment 
(including name, intended context for use, administra-
tion method, number of scales or subscales, number of 
items, response options, recall period and information 
about interpretability and feasibility) and the method-
ological quality ratings of each study, per measurement 
property, per BTP assessment tool. KG will extract this 
information which will be subsequently checked by DS, 
with any disagreements resolved through discussion with 
CL.
Both KG and DS will independently undertake a 
quality appraisal of studies included from search 2, after 
reading and familiarisation with the COSMIN checklist 
development, manual and scoring system.29 34 Disagree-
ments will be resolved by discussion between KG and DS, 
and CL if required. In line with the COSMIN guidelines 
for conducting systematic reviews of patient- reported 
outcome measures (PROMs),29 the following steps will be 
taken to assess quality:
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1. Methodological quality of each individual study on 
a measurement property will be assessed using the 
COSMIN Risk of Bias checklist.37
2. The result of each study on a measurement property 
will be assessed using the COSMIN updated criteria for 
good measurement properties.34
3. The quality of the evidence per measurement property 
per assessment will be graded and summarised.
Assessing risk of bias
For step 1, we will use the COSMIN Risk of Bias check-
list,37 which is comprised of 10 items (or boxes). One 
box assesses standards for PROMs and nine assess the 
following measurement properties: content validity, 
structural validity, internal consistency, cross‐cultural 
validity, reliability, measurement error, criterion validity 
(including sensitivity and specificity for dichotomous 
scores), hypotheses testing for construct validity and 
responsiveness (see table 1 for definitions). Only check-
list items that are assessed in each included study will be 
completed since not all measurement properties are eval-
uated in all articles. Studies will be given an overall rating 
of very good, adequate, doubtful or inadequate quality.
Assessing psychometric properties
The psychometric property of each BTP assessment will 
then be rated as sufficient, insufficient or inconsistent 
using the updated criteria for good measurement prop-
erties (see table 2).34
Summarising and grading the quality of the evidence
Step 3 focuses on the quality of each BTP assessment as a 
whole as opposed to the quality of each study, which was 
the focus of steps 1 and 2. This first involves reviewing 
the extracted data to establish whether the results of all 
studies of the same BTP assessment are consistent.
Meta-analysis of psychometric properties
Following scoping searches of current available literature 
together with the heterogeneity of the clinical population, 
pooling of data in a meta- analysis may not be possible; 
however, it will not be ruled out and will be assessed prior 
to synthesis and conducted if possible.
Initially we considered psychometric meta- 
analysis38 39; however, we opted for conventional meta- 
analytic techniques due to current disagreements in the 
field regarding various aspects of the technique and that 
simulations have reported trivial differences between the 
two in most cases.40 Briefly, Hunter and Schmidt’s meta- 
analytic approach38 39 is based on psychometric principles 
and contends that a substantial portion of the variability 
observed in an X- Y relationship across primary- level 
studies is the result of artifactual sources of variance (eg, 
sampling error, measurement error in the dependent 
or criterion variable, range restriction). Consequently, 
to estimate better moderators of the X- Y relationship in 
the population, meta- analysts should correct for artifac-
tual across- study variability by controlling it via research 
design and/or subtracting it from the total observed 
variance. Many artefact- correction procedures and tech-
niques have been developed and are applied with some 
disagreements to the optimum ones. Other differences 
to conventional meta- analysis include, among others, 
emphasis on credulity intervals rather than overall 
means and use of correlation coefficients instead of Fish-
er’s Z transformed values, and the 75% rule to assess 
heterogeneity.
We selected Fisher’s Z, which ranges from −∞ to +∞ and 
can be interpreted similar to a correlation coefficient, 
as the standardised common effect size. Depending on 
which measurement properties have been assessed and 
which estimates reported, intraclass correlations, as well 
as Pearson and Spearman correlations, will be converted 
to Fisher’s Z using Fisher’s variance stabilising transfor-
mation.41 42 F- ratios and unstandardised beta coefficients 
will be converted to r and then to Fisher’s Z.41 42 Exact 
p values, if no other test statistic is available, will be 
converted to a standard normal deviate (Z- score), then 
to r, and then to Fisher’s Z.41 Studies reporting effect 
sizes derived from >2 follow- up assessments will be coded 
for both the entire study follow- up length (ie, one effect 
size per psychometric property, per study) and shorter, 
non- overlapping follow- up intervals (eg, 2–4 weeks, 4–6 
weeks). Analyses will be age- stratified due to noted meth-
odological differences between studies with younger and 
older children and adults.
All analyses will be completed using Comprehensive 
Meta- Analysis V.3.43 Random- effects models will be used, 
which assume the average effect size varies between 
studies and therefore heterogeneity is to be expected. To 
examine heterogeneity, two statistics will be reported and 
examined: the Cochrane’s Q test and the I2 statistic. With 
the Cochrane’s Q test, a significant result is indicative of 
heterogeneity of effects. Caution is advocated in the inter-
pretation of this statistic, however, since it has low power 
when analyses are performed with few studies or with 
small sample sizes.44 Instead of testing whether heteroge-
neity is present, the I² statistic describes the percentage 
of variability in effect estimates due to heterogeneity as 
opposed to sampling error.45 A rough guide for the inter-
pretation of the I² statistic is provided by the Cochrane 
Handbook: 0%–40%: might not be important; 30%–60%: 
may represent moderate heterogeneity; 50%–90%: may 
represent substantial heterogeneity; 75%–100%: consid-
erable heterogeneity.44 If evidence of significant hetero-
geneity exists, then, where appropriate, sensitivity analyses 
will be conducted to verify the robustness of meta- analytic 
results. Funnel plots will also be created and examined to 
detect potential reporting biases and small- study effects 
for all analyses that include data from more than 10 
studies.44
If statistical pooling of results is not possible, the find-
ings from different studies on each measurement prop-
erty per BTP assessment will be qualitatively summarised, 
which will include a summarised result (eg, for hypoth-
esis testing for construct validity, the percentage of results 
that are in accordance with the hypothesis will be listed). 
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Table 2 COSMIN updated criteria for good measurement properties34
Measurement 
property Rating Criteria
Structural validity Sufficient (+) Classical test theory (CTT):
Confirmatory factor analysis: comparative fit index (CFI) or Tucker- Lewis index (TLI) or comparable 
measure >0.95 or root mean square error of approximation (RMSEA) <0.06 or standardised root 
mean residuals (SRMR) <0.08
Item response theory (IRT)/Rasch: All of the following
 ► No violation of unidimensionality: CFI or TLI or comparable measure >0.95 OR RMSEA <0.06 
OR SRMR <0.08)
 ► No violation of local independence: residual correlations among the items after controlling for 
the dominant factor <0.20 OR Q3's<0.37
 ► No violation of monotonicity: adequate looking graphs or item scalability >0.30 and adequate 
model fit: IRT: χ2>0.01; Rasch: infit and outfit mean squares ≥0.5 and ≤1.5 OR Z standardised 
values > −2 and <2
Indeterminate (?) CTT: Not all information required for a sufficient rating is reported
IRT/Rasch: Model fit not reported
Insufficient (−) Criteria for sufficient rating not met
Internal consistency + At least low evidence for sufficient structural validity (assessed using GRADE)46 and Cronbach's 
alpha(s)≥0.70 for each unidimensional scale or subscale)
? Criteria for low evidence or higher not met
– At least low evidence for sufficient structural validity and Cronbach’s alpha(s)<0.70 for each 
unidimensional scale or subscale
Reliability + Intraclass correlation coefficient (ICC) or weighted Kappa ≥0.70
? ICC or weighted Kappa not reported
– ICC or weighted Kappa <0.70
Measurement error + Smallest detectable change (SDC) or limits of agreement (LoA) <minimal important change (MIC)
? MIC not defined
– SDC or LoA >MIC
Hypotheses testing for 
construct validity
+ 75% or more of the results from all studies are in accordance with the hypotheses
? No hypotheses defined (by review team)
– Results are not in accordance with the hypotheses
Cross‐cultural 
validity/measurement 
invariance
+ No important differences found between group factors (eg, age) in multiple group factor analysis 
or no important differential item functioning (DIF) for group factors (McFadden's R2 <0.02)
? No multiple group factor analysis OR DIF analysis performed
– Important differences between group factors or DIF found
Criterion validity + Correlation with gold standard ≥0.70 OR area under curve (AUC) ≥0.70
? Not all information for sufficient rating reported
– Correlation with gold standard <0.70 OR AUC <0.70
Responsiveness + Result is in accordance with the hypothesis or AUC ≥0.70
? No hypotheses defined (by review team)
– Results are not in accordance with the hypotheses or AUC <0.70
COSMIN, COnsensus- based Standards for the selection of health Measurement INstruments.
These results (quantitative and/or qualitative) will be 
displayed in a summary of findings table.
If the results of studies that involve the same BTP 
assessment are inconsistent, explanations for this will be 
explored and results will be summarised per subgroup of 
consistent results where possible. For example, an assess-
ment may be sufficiently reliable for use in adults but not 
in children so results will be summarised by population 
age group. If no explanation for inconsistent results can 
be found, the rating of the majority of the results will be 
used.
The measurement property of each BTP assessment 
will then be rated as sufficient, insufficient or inconsistent 
using the updated criteria for good measurement proper-
ties.34 Finally, the quality of the evidence (our confidence 
that the summarised result is trustworthy) will be rated 
using a modified version of the GRADE guidelines.46 This 
involves grading the evidence as high, moderate, low or 
very low quality based on four factors: risk of bias, incon-
sistency, indirectness and imprecision. These overall 
ratings and GRADE assessments will be included in the 
summary of findings table.
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Outcomes
The main outcomes are to identify, critically appraise 
and compare, and summarise all available instruments 
assessing BTP in infants, children or adults, using 
COSMIN criteria.
A table of the identified BTP instruments will be 
presented along with a summary of findings table per 
measurement property, which will include the pooled 
results of the measurement properties, an overall rating 
and a grade of the quality of the evidence.
The interpretability (the extent to which clinical or 
commonly understood meanings can be assigned to 
scores) and feasibility (ease of application) of these BTP 
assessment tools will be described. We will then formu-
late recommendations for the most appropriate BTP 
assessment tool(s) based on the earlier findings. Where 
possible, these will be formulated by disease and age 
groups (children and adults) separately. The included 
assessments will be categorised into (1) the most suitable 
assessments (ie, those with high evidence of sufficient 
content validity and low evidence for internal incon-
sistency); (2) assessments that need further validation 
before they can be recommended and (3) assessments 
that are not recommended (ie, due to high evidence for 
an inadequate measurement property).
Patient and public involvement
Funding bodies and the wider scientific community 
currently expect that researchers actively involve patients 
and the public in their research, including systematic 
reviews. Active patient and public involvement (PPI) 
within systematic reviews, in particular, has been proposed 
as a way to enhance the actual and perceived usefulness 
of synthesised research evidence, therefore addressing 
barriers to the uptake of evidence into practice.47
PPI is represented in the authorship of this system-
atic review. MJ is involved at key stages of this systematic 
review, that is, development of the research question, 
helping to determine the appropriate inclusion and 
exclusion criteria and identifying search terms and rele-
vant outcomes, and peer reviewing academic papers.
MJ is one of the PPI representatives at the UK National 
Institute for Health Research Pain and Palliative Care Clin-
ical Studies Group- Children and is a member of the PPI 
group for the Primary Care Unit Palliative Care and End 
of Life Research Group at the University of Cambridge 
Department of Public Health and Primary Care. MJ is also 
a trustee and board member of The Childhood Cancer 
Parents Alliance and a member of the National Cancer 
Research Institute Consumer Forum.
dIsCussIOn
To our knowledge, this will be the first systematic review 
to identify all available BTP instruments and review and 
summarise the psychometric properties of these assess-
ments. For BTP to be effectively managed, reliable 
ongoing assessment is critical.
The dearth and/or heterogeneity of the included 
studies, which may not report on the same psychometric 
properties, or may lack sufficient detail on these, could 
limit the overall review and subsequent recommenda-
tions. The findings will be used to inform healthcare 
professionals on the most appropriate BTP assessment 
tools for different populations and will highlight gaps in 
BTP assessment research.
Ethics and dissemination
Due to no patient data being accessed or collated, no 
research ethics is required for this systematic review. 
Results of this review will be submitted for publication in 
a peer review journal and presented at conferences.
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